HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Spero Therapeutics (NASDAQ:SPRO) and maintained a $6 price target.
July 20, 2023 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spero Therapeutics (NASDAQ:SPRO) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $6.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for the stock. The maintained price target of $6 indicates the firm's continued confidence in the stock's potential. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100